Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A S Cheifetz

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Alimentary Pharmacology & Therapeutics|January 10, 2018
Editorial: early post-induction anti-TNF drug monitoring can predict long-term therapeutic outcomes in inflammatory bowel diseaseK Papamichael, A S Cheifetz
Alimentary Pharmacology & Therapeutics|April 4, 2017
Editorial: therapeutic de-escalation of anti-tumour necrosis factor therapy - is less enough?K Papamichael, A S Cheifetz
Alimentary Pharmacology & Therapeutics|April 18, 2013
Commentary: irritable bowel syndrome and the CDAI--misleading activity by straw men; authors' replyC Lahiff, A S Cheifetz
Alimentary Pharmacology & Therapeutics|April 13, 2018
Letter: infliximab concentrations during induction therapy-one size does not fit allK Papamichael, A S Cheifetz
Alimentary Pharmacology & Therapeutics|July 2, 2013
Letter: international IBD practice guidelines -- authors' replyJ D Feuerstein, D A Leffler, A S Cheifetz
Alimentary Pharmacology & Therapeutics|July 17, 2013
Letter: inflammatory bowel disease guidelines and conflicts of interest--authors' replyJ D Feuerstein, D A Leffler, A S Cheifetz
Alimentary Pharmacology & Therapeutics|October 1, 2011
Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literatureG Cullen, D Kroshinsky, A S Cheifetz, et al.
Alimentary Pharmacology & Therapeutics|January 14, 2012
Outcomes after escalation of infliximab therapy in ambulatory patients with moderately active ulcerative colitisE Rostholder, A Ahmed, A S Cheifetz, et al.
Alimentary Pharmacology & Therapeutics|December 7, 2017
Infliximab trough concentrations during maintenance therapy are associated with endoscopic and histologic healing in ulcerative colitisK Papamichael, S Rakowsky, C Rivera, et al.
Gastroenterology|January 31, 2007
Clinical challenges and images in GI. Oral lichenoid reaction in a patient with Crohn's disease receiving infliximabA C Moss, N S Treister, D K Marsee, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Alimentary Pharmacology & Therapeutics|January 10, 2018
Editorial: early post-induction anti-TNF drug monitoring can predict long-term therapeutic outcomes in inflammatory bowel diseaseK Papamichael, A S Cheifetz
Alimentary Pharmacology & Therapeutics|April 4, 2017
Editorial: therapeutic de-escalation of anti-tumour necrosis factor therapy - is less enough?K Papamichael, A S Cheifetz
Alimentary Pharmacology & Therapeutics|April 18, 2013
Commentary: irritable bowel syndrome and the CDAI--misleading activity by straw men; authors' replyC Lahiff, A S Cheifetz
Alimentary Pharmacology & Therapeutics|April 13, 2018
Letter: infliximab concentrations during induction therapy-one size does not fit allK Papamichael, A S Cheifetz
Alimentary Pharmacology & Therapeutics|July 2, 2013
Letter: international IBD practice guidelines -- authors' replyJ D Feuerstein, D A Leffler, A S Cheifetz
Alimentary Pharmacology & Therapeutics|July 17, 2013
Letter: inflammatory bowel disease guidelines and conflicts of interest--authors' replyJ D Feuerstein, D A Leffler, A S Cheifetz
Alimentary Pharmacology & Therapeutics|October 1, 2011
Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literatureG Cullen, D Kroshinsky, A S Cheifetz, et al.
Alimentary Pharmacology & Therapeutics|January 14, 2012
Outcomes after escalation of infliximab therapy in ambulatory patients with moderately active ulcerative colitisE Rostholder, A Ahmed, A S Cheifetz, et al.
Alimentary Pharmacology & Therapeutics|December 7, 2017
Infliximab trough concentrations during maintenance therapy are associated with endoscopic and histologic healing in ulcerative colitisK Papamichael, S Rakowsky, C Rivera, et al.
Gastroenterology|January 31, 2007
Clinical challenges and images in GI. Oral lichenoid reaction in a patient with Crohn's disease receiving infliximabA C Moss, N S Treister, D K Marsee, et al.
Pageof 2